It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Resistance to radiotherapy is a major barrier during cancer treatment. Here using genome-scale CRISPR/Cas9 screening, we identify CD274 gene, which encodes PD-L1, to confer lung cancer cell resistance to ionizing radiation (IR). Depletion of endogenous PD-L1 delays the repair of IR-induced DNA double-strand breaks (DSBs) and PD-L1 loss downregulates non-homologous end joining (NHEJ) while overexpression of PD-L1 upregulates NHEJ. IR induces translocation of PD-L1 from the membrane into nucleus dependent on deglycosylation of PD-L1 at N219 and CMTM6 and leads to PD-L1 recruitment to DSBs foci. PD-L1 interacts with Ku in the nucleus and enhances Ku binding to DSB DNA. The interaction between the IgC domain of PD-L1 and the core domain of Ku is required for PD-L1 to accelerate NHEJ-mediated DSB repair and produce radioresistance. Thus, PD-L1, in addition to its immune inhibitory activity, acts as mechanistic driver for NHEJ-mediated DSB repair in cancer.
Resistance to radiotherapy is a major barrier during cancer treatment. Here the authors find that radiation-induced DNA double-strand-breaks (DSBs) facilitate PD-L1 deglycosylation and translocation into the nucleus, leading to promotion of NHEJ-mediated DSB repair and lung cancer radioresistance.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Emory University School of Medicine and Winship Cancer Institute of Emory University, Department of Radiation Oncology, Atlanta, USA (ISNI:0000 0004 0413 0929)
2 Emory University, Bioinformatics and Systems Biology Shared Resource, Winship Cancer Institute, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
3 Emory University, Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0004 1936 7398)
4 Emory University School of Medicine and Winship Cancer Institute of Emory University, Department of Radiation Oncology, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0004 0413 0929)